12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BM32: Phase IIb ongoing

Biomay said an independent DMC recommended continuation of a double-blind, placebo-controlled, European Phase IIb trial of BM32 into the next treatment year based on a review of symptom medication score and safety data from the first treatment year. The trial,...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >